Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant, dose-dependent weight loss in adults with obesity (BMI ≥30 or ≥27 with comorbidities) and type 2 diabetes, outperforming placebo, semaglutide, and insulin glargine.
Tirzepatide is a once-weekly injectable medication for obesity and type 2 diabetes that works by mimicking two gut hormones (GIP and GLP-1). It significantly reduces body weight (up to ~21% in clinical trials) and improves blood sugar control. It is more effective than semaglutide and insulin glargine for weight loss. Common side effects include nausea and diarrhea, which usually improve over time. It requires a prescription and medical supervision.
At 72 weeks, a reduction in body weight proportional to the dosage of tirzepatide used was obtained as follows: a change of -15% ... was observed with 5-mg weekly doses of tirzepatide; a change of -19.5% ... was observed with 10-mg weekly doses of tirzepatide; a change of -20.9% ... was observed with 15-mg doses of tirzepatide; and a change of -3.1% ... was observed with the placebo (p<0.001 for all comparisons to placebo).
Why this rating
Based on multiple large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical trials (SURPASS-1, SURMOUNT-1).
Source
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Isabella Zaffina et al. · Frontiers in Endocrinology · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →